Phase I Dose Escalation Trial of the Novel Proteasome Inhibitor Carfilzomib in Patients with Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

The proteasome complex degrades proteins involved in a variety of cellular processes and is a powerful therapeutic target in several malignancies. Carfilzomib is a potent proteasome inhibitor which induces rapid CLL cell apoptosis in vitro. We conducted a phase I dose-escalation trial to determine s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leuk Lymphoma
Main Authors: Awan, Farrukh T., Flynn, Joseph M., Jones, Jeffrey A., Andritsos, Leslie A., Maddocks, Kami J., Sass, Ellen J., Lucas, Margaret S., Chase, Weihong, Waymer, Sharon, Ling, Yonghua, Jiang, Yao, Phelps, Mitch A., Byrd, John C., Lucas, David M., Woyach, Jennifer A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4835239/
https://ncbi.nlm.nih.gov/pubmed/25669927
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2015.1014368
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados